SNMMI SmartBrief

Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/ejBaCfbwocfbgTktoxDA

February 11, 2013

Forward

Read more at SmartBrief.com

News for nuclear medicine and molecular imaging professionals

The news summaries appearing in SNMMI SmartBrief are based on original information from multiple internet sources and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The items below are not selected or reviewed by SNMMI prior to publication. Questions and comments may be directed to SmartBrief at snmmi@smartbrief.com.

Top Story

Study: In-room PET useful for monitoring proton therapy
In-room PET imaging while patients are undergoing proton therapy allows for treatment monitoring while avoiding problems related to moving a patient to a new room for scanning, according to a study published in the International Journal of Radiation Oncology*Biology*Physics. "We found that the standalone in-room PET scanner on wheels could be promptly positioned after radiation delivery in as little as two minutes, and this represents a reasonable system that could be replicated at other proton facilities," researchers said. MolecularImaging.net (2/8)

Finally, a practical way to personalize PET doses.
The MEDRAD™ Intego™ PET Infusion System utilizes a fully shielded, mobile design with integrated dosimetry to enable clinicians to determine and administer an accurate, personalized dose for each patient. To see how the MEDRAD™ Intego™ is supporting better patient care, click here.

Clinical News & Research

SUVmax sheds light on prognosis for patients with NSCLC
Maximum standardized uptake value as measured by PET/CT may help improve prediction of progression-free survival in patients with early-stage non-small cell lung cancer undergoing stereotactic body radiation therapy, according to findings presented at an imaging and radiation therapy conference. The study involved patients who had PET/CT imaging with SUVmax assessment before undergoing treatment. SUVmax assessment may allow for more tailored treatment strategies and ultimately better outcomes, a researcher said. AuntMinnie.com (free registration) (2/8)

Industry Report

Expert: FDA guidance for Alzheimer's drugs should help industry
New draft guidance for the development of drugs targeting the early stages of Alzheimer's disease will assist drugmakers with the design of clinical trials aimed at detecting disease before the onset of dementia, said Dr. Paul Aisen, director of the Alzheimer's Disease Cooperative Study. "I think this will be hugely useful to the pharmaceutical industry," he said. The Columbus Dispatch (Ohio)/Reuters (2/8)

Career as a technologist pays, CareerBuilder finds
Nuclear medicine technology and radiation therapy are among the top-paying careers that require only an associate degree, according to CareerBuilder and Economic Modeling Specialists. The list is based on information from nearly 100 resources. TheGrindstone.com (2/8)

News from the Field

Program to develop CTC detection tech gains support
Roche Holding has entered a deal with Uppsala BIO to back Liquid Biopsy's effort to devise new technology for circulating tumor cell detection. The effort is also supported by BIO-X, an initiative focused on the development of advanced diagnostics. GenomeWeb Daily News (free registration) (2/7)

International Developments

India sets rules for clinical study approval, inspection
The Indian Health Ministry is changing its Drugs and Cosmetics Rules to include terms for approving clinical trials and inspecting sites. The rules require registration with the Clinical Trials Registry of India prior to the enrollment of patients. PharmaBiz.com (India) (2/7)

Health Policy

Senate bill takes aim at 2.3% medical device tax
A bipartisan bill that would repeal the 2.3% medical device tax has been introduced in the Senate. Industry leaders and lawmakers in favor of the repeal said the tax will threaten job growth and medical innovation. "In order to compete in the global economy, our medical device businesses need a level playing field," said Sen. Amy Klobuchar, D-Minn. Reuters (2/7)

Advancing Health Care

Personalized medicine puts a new face on drug research
Drugmakers increasingly use genetic data to select for early-stage clinical trials patients who are likely to benefit from the experimental drug. The strategy could reduce the time it takes to get a new drug approved with less money wasted on ineffective trials, experts say. The Wall Street Journal (2/7)

From SNMMI

Mallinckrodt provides additional information on Dutch High-Flux Reactor
On Jan. 30, Mallinckrodt issued a customer letter stating the status and additional news, provided by the NRG, for the Dutch High-Flux Reactor (HFR).

Uniform Protocols in Clinical Trials (UPICT) Standardized FDG-PET/CT Protocol: Progress and Updates webinar: Feb. 14
Join Jeffrey Yap, Ph.D. — Feb. 14 at 3 p.m. ET — as he reviews the progress made by UPICT with an emphasis on the importance of using standardizing imaging protocols. Attendees will gain valuable information that can be easily adopted into their clinical research activities. Register today!

SmartQuote

The only man I know who behaves sensibly is my tailor; he takes my measurements anew each time he sees me. ... The rest go on with their old measurements and expect me to fit them."

--George Bernard Shaw,
Irish playwright

Subscriber Tools

Print friendly format | Web version | Search past news | Archive | Privacy policy

Advertise

Account Director: Meryl Harold (202) 407-7828

Download Media Kit